Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CS17 Bovine IgG is a preparation of immunoglobulin G (IgG) antibodies derived from the colostrum of cows immunized with the CS17 colonization factor antigen from enterotoxigenic Escherichia coli (ETEC). These antibodies are administered orally and have been shown in clinical trials to provide significant protection against diarrhea caused by ETEC strains expressing the CS17 fimbrial antigen. The mechanism of action involves passive immunization, where orally delivered bovine IgG binds to and neutralizes the CS17 fimbriae on ETEC, preventing bacterial adhesion to intestinal epithelial cells and subsequent infection[1][2][5]. This approach is considered a form of oral immunotherapy for infectious diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-cs17 bovine igg.